Conditional EU approval for Roche’s Erivedge
The European Commission granted conditional approval to Roche’s Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy.
Today’s approval makes Erivedge the first licensed medicine for patients in the European Union with this form of skin cancer.
Roche will provide additional data on Erivedge in advanced BCC from an ongoing global safety study to satisfy the provisions of the conditional approval.
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.